Form 6-K Concordia International For: May 07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May 2018
Commission File Number: 001- 37413
Concordia International Corp.
(Translation of registrant’s name into English)
277 Lakeshore Road East, Suite 302
Oakville, Ontario
L6J 1H9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
On May 7, 2018, Concordia International Corp. (“Concordia”) issued a press release announcing the release date for its financial results for the first quarter ended March 31, 2018. In conjunction with this announcement Concordia is filing the following exhibits:
Exhibit 99.1 Press release of Concordia International Corp., dated May 7, 2018
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Concordia International Corp. | |||
By: | /s/ David Price | ||
Name: | David Price | ||
Title: | Chief Financial Officer | ||
Date: May 7, 2018
EXHIBIT INDEX
Exhibit No. | Description |
Exhibit 99.1 | |
Concordia International Corp. Announces Release Date for First Quarter 2018 Results
OAKVILLE, ON, May 7, 2018 – Concordia International Corp. (“Concordia” or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its first quarter 2018 financial results before market open on Tuesday, May 15, 2018.
The Company will subsequently hold a conference call that same day, Tuesday, May 15, 2018, at 8:30 a.m. ET hosted by Mr. Graeme Duncan, interim Chief Executive Officer, and other senior management. A question-and-answer session will follow the corporate update.
CONFERENCE CALL DETAILS | |
DATE: | Tuesday, May 15, 2018 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBER: | (647) 427-7450 or (888) 231-8191 |
TAPED REPLAY: | (416) 849-0833 or (855) 859-2056 |
REFERENCE NUMBER: | 6279535 |
This call is being webcast and can be accessed by going to:
An archived replay of the webcast will be available by clicking the link above.
About Concordia
Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. Going forward, the Company is focused on becoming a leader in European specialty, off-patent medicines.
Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
Notice regarding forward-looking statements and information:
This news release includes forward‐looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward‐looking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to, statements with respect to the release date of Concordia's financial results. The forward‐looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks associated with Concordia's securities, increased indebtedness and leverage, Concordia's growth,
risks associated with the use of Concordia's products, the inability to generate cash flows, revenues and/or stable margins, the inability to repay debt and/or satisfy future obligations, risks associated with a delay in releasing Concordia's financial statements (which could result in a default under Concordia's debt agreements and a violation of applicable laws), Concordia's outstanding debt, risks associated with the geographic markets in which Concordia operates and/or distributes its products, risks associated with distribution agreements, the pharmaceutical industry and the regulation thereof, regulatory investigations, the failure to comply with applicable laws, economic factors, market conditions, risks associated with growth and competition, the failure to obtain regulatory approvals, the equity and debt markets generally, general economic and stock market conditions, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), political risks (including changes to political conditions), risks associated with the United Kingdom's exit from the European Union (including, without limitation, risks associated with regulatory changes in the pharmaceutical industry, changes in cross‐border tariff and cost structures and the loss of access to the European Union global trade markets), risks related to patent infringement actions, the loss of intellectual property rights, risks and uncertainties detailed from time to time in Concordia's filings with the Securities and Exchange Commission and the Canadian Securities Administrators, and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward‐looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward‐looking statement or information can be guaranteed. Except as required by applicable securities laws, forward‐looking statements and information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward‐looking statement or information, whether as a result of new information, future events, or otherwise.
For more information please contact:
Adam Peeler
Concordia International Corp.
905-842-5150 x 240